Cardinal Health Executive Compensation (FY25)
CAH · Executive and director compensation, fiscal 2022 to 2025
The Cardinal Health brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
Data as of September 7, 2026Latest filing (8-K): November 6, 2025
13 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
$1,500Get the executive brief
259 figures on this page: 249 cited to the filing that reported them, 10 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Jason Hollar: $25,650,709 → $18,976,195 (26.0% lower)
Say-on-pay support: 89.6% → 90.7% (1.1 points higher)
CEO pay ratio: 457:1 → 261:1 (42.9% lower)
Frequently asked questions
Answers drawn from the data on this page.
Who is Cardinal Health's chief executive and what were they paid?
Jason Hollar, Chief Executive Officer, received $18,976,195 in total compensation for fiscal 2025. Compared with the $25,650,709 reported for fiscal 2024, Hollar's total was 26.0% lower.
What was Cardinal Health's say-on-pay result?
The say-on-pay proposal drew 90.7% of votes cast for or against in favor at the meeting held November 5, 2025 for fiscal 2025.
Which companies are in Cardinal Health's peer group?
The disclosed peer group includes Baxter International Inc., Becton, Dickinson and Company, Boston Scientific Corporation, Cencora, Inc. and CVS Health Corporation, among others.
What is Cardinal Health's chief executive pay ratio?
The disclosed chief executive pay ratio for fiscal 2025 is 261:1, against median employee compensation of $72,657.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Michael Kaufmann Former Chief Executive Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Jessica Mayer Chief Legal and Compliance Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Jason Hollar Chief Executive Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Victor Crawford Former Chief Executive Officer, Pharmaceutical Segment | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Stephen Mason Chief Executive Officer, Global Medical Products and Distribution Segment | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Jason Hollar Chief Executive Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Aaron Alt Chief Financial Officer | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Victor Crawford Former Chief Executive Officer, Pharmaceutical Segment Departed during or after this year | ◇ | — | ◇ | — | — | — | ◇ | ◇ |
Stephen Mason Chief Executive Officer, Global Medical Products and Distribution Segment | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Jessica Mayer Chief Legal and Compliance Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Deborah Weitzman Chief Executive Officer, Pharmaceutical and Specialty Solutions Segment | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Michael Kaufmann Former Chief Executive Officer Departed during or after this year | ◇ | — | — | — | — | — | ◇ | ◇ |
Patricia English Former Interim Chief Financial Officer Departed during or after this year Served on an interim basis | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Jason Hollar Chief Executive Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Stephen Mason Chief Executive Officer, Global Medical Products and Distribution Segment | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Aaron Alt Chief Financial Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Deborah Weitzman Chief Executive Officer, Pharmaceutical and Specialty Solutions Segment | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Jessica Mayer Chief Legal and Compliance Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Jason Hollar Chief Executive Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Aaron Alt Chief Financial Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Deborah Weitzman Chief Executive Officer, Pharmaceutical and Specialty Solutions Segment | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Jessica Mayer Chief Legal and Compliance Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Stephen Mason Chief Executive Officer, Global Medical Products and Distribution Segment | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Aaron Alt | PSU | ◇ | — | ◇ | — | ◇ | — | ◇ |
| Aaron Alt | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Deborah Weitzman | PSU | ◇ | — | ◇ | — | ◇ | — | ◇ |
| Deborah Weitzman | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Jason Hollar | PSU | ◇ | — | ◇ | — | ◇ | — | ◇ |
| Jason Hollar | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Jessica Mayer | PSU | ◇ | — | ◇ | — | ◇ | — | ◇ |
| Jessica Mayer | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Stephen Mason | PSU | ◇ | — | ◇ | — | ◇ | — | ◇ |
| Stephen Mason | RSU | ◇ | — | — | ◇ | — | — | ◇ |
Fiscal 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Deborah Weitzman | PSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| Stephen Mason | PSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| Aaron Alt | PSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| Jessica Mayer | RSU | ◇ | ◇ | — | — |
| PSU | ◇ | ◇ | — | — | |
| Jason Hollar | PSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Gregory B. Kenny Board chair | ◇ | ◇ | — | — | — | — | ◇ |
Akhil Johri | ◇ | ◇ | — | — | — | ◇ | ◇ |
Patricia A. Hemingway Hall | ◇ | ◇ | — | — | — | ◇ | ◇ |
Sheri H. Edison | ◇ | ◇ | — | — | — | — | ◇ |
Nancy Killefer | ◇ | ◇ | — | — | — | — | ◇ |
Robert W. Azelby | ◇ | ◇ | — | — | — | ◇ | ◇ |
David C. Evans | ◇ | ◇ | — | — | — | ◇ | ◇ |
Christine A. Mundkur | ◇ | ◇ | — | — | — | — | ◇ |
Michelle M. Brennan | ◇ | ◇ | — | — | — | — | ◇ |
Robert W. Musslewhite | ◇ | ◇ | — | — | — | — | ◇ |
Sudhakar Ramakrishna | ◇ | ◇ | — | — | — | — | ◇ |
Steven K. Barg | ◇ | — | — | — | — | — | ◇ |
Sujatha Chandrasekaran | ◇ | — | — | — | — | — | ◇ |
Jason M. Hollar served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Audit committee chair | ◇ |
| Compensation committee chair | ◇ |
| Nominating and governance chair | ◇ |
Equity is delivered as restricted stock units.
Stock ownership guideline: 5x cash retainer
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- Baxter International Inc. BAX
- Becton, Dickinson and Company BDX
- Boston Scientific Corporation BSX
- Cencora, Inc. COR
- CVS Health Corporation CVS
- Danaher Corporation DHR
- Elevance Health, Inc. ELV
- FedEx Corporation FDX
- Henry Schein, Inc. HSIC
- Johnson & Johnson JNJ
- Labcorp Holdings Inc. LH
- McKesson Corporation MCK
- Medtronic plc MDT
- Owens & Minor, Inc. symbol not shown
- Stryker Corporation SYK
- Sysco Corporation SYY
- Target Corporation TGT
- The Cigna Group CI
- The Kroger Co. KR
- Thermo Fisher Scientific Inc. TMO
- United Parcel Service, Inc. UPS
- UnitedHealth Group Incorporated UNH
- Walgreens Boots Alliance, Inc. WBA
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | November 5, 2025 | = | ◇ | ◇ | ◇ |
| 2024 | November 6, 2024 | = | ◇ | ◇ | ◇ |
| 2023 | November 15, 2023 | = | ◇ | ◇ | ◇ |
| 2022 | November 9, 2022 | = | ◇ | ◇ | ◇ |
| 2021 | November 5, 2021 | = | ◇ | ◇ | ◇ |
| 2020 | November 4, 2020 | = | ◇ | ◇ | ◇ |
| 2019 | November 6, 2019 | = | ◇ | ◇ | ◇ |
| 2018 | November 7, 2018 | = | ◇ | ◇ | ◇ |
| 2017 | November 8, 2017 | = | ◇ | ◇ | ◇ |
| 2016 | November 3, 2016 | = | ◇ | ◇ | ◇ |
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
What this page does not include
Everything above is a fact Cardinal Health disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Cardinal Health sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
259 figures on this page: 249 cited to the filing that reported them, 10 calculated from figures it prints.
249 cited to the filing
10 calculated from the filing
Documents cited
- 0000721371-25-000133Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000721371-25-000114CEO Pay Ratio · Director Compensation · Director Compensation for Fiscal 2025 · Grants of Plan-Based Awards · and 2 more sections
- 0000721371-24-000132Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000721371-24-000103Executive Compensation Tables · Summary Compensation Table
- 0000721371-23-000094Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001308179-23-001007Summary Compensation Table
- 0000721371-22-000144Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000721371-21-000120
- 0000721371-20-000133
- 0000721371-19-000129Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000721371-18-000104Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000721371-17-000169Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000721371-16-000353
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Cardinal Health executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/CAH (accessed 2026).
Short form: data: Velarion
The Cardinal Health brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
13 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Cardinal Health and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Peers Cardinal Health discloses
The companies named in CAH's own disclosed peer group.
Baxter International Inc.Becton, Dickinson and CompanyBoston Scientific CorporationCencora, Inc.CVS Health CorporationDanaher CorporationElevance Health, Inc.FedEx CorporationHenry Schein, Inc.Johnson & JohnsonLabcorp Holdings Inc.McKesson CorporationMedtronic plcStryker CorporationSysco CorporationTarget CorporationThe Cigna GroupThe Kroger Co.Thermo Fisher Scientific Inc.United Parcel Service, Inc.UnitedHealth Group IncorporatedWalgreens Boots Alliance, Inc.
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}